Breakthrough Medicine Study Slashes Diabetes Risk by 94%

Breakthrough medicine study slashes diabetes risk by 94%: Revolutionary weight loss drug shows remarkable results.

In a landmark three-year study, tirzepatide – marketed as Mounjaro for diabetes and Zepbound for weight loss—demonstrated an astounding 94% reduction in the risk of progressing from prediabetes to diabetes among adults with obesity or overweight when administered weekly, according to Eli Lilly.

The drug, produced by Eli Lilly and Company, also led to a nearly 23% average decrease in body weight for those on the 15-milligram dose, starkly contrasting with a 2.1% reduction in the placebo group.

However, a 17-week follow-up period revealed that discontinuation of tirzepatide resulted in some weight regain and a slight increase in diabetes progression.

Gastrointestinal issues, such as diarrhea, nausea, constipation, and vomiting, were the most common side effects, but they were generally mild to moderate.

Prediabetes, affecting about one in three adults in the U.S. and a precursor to diabetes, is typically managed through lifestyle changes, with weight loss being a key factor. Tirzepatide works by mimicking hormones that boost insulin release, enhance feelings of fullness, and reduce appetite, targeting GIP and GLP-1 receptors.

The drug, which has already shown greater weight loss compared to other medications in previous trials, was recently approved by the FDA for individuals with obesity or weight-related health conditions. It is administered via weekly injections and is recommended alongside a reduced-calorie diet and increased exercise.

Eli Lilly plans to submit the new study results to a peer-reviewed journal and present them at ObesityWeek 2024 in November.

Breakthrough medicine study slashes diabetes risk. Revolutionary weight loss drug shows remarkable results.

-CNN